Artios Pharma Limited, a British biopharmaceutical firm dedicated to realising the therapeutic potential of concentrating on the DNA harm response (DDR) in most cancers, at this time introduced the profitable shut of an oversubscribed €99 million ($115 million) Collection D financing.
The buyers who supported the spherical embrace Andera Companions, Avidity Companions, EQT Life Sciences, Invus, IP Group plc, Janus Henderson Buyers, M Ventures, Novartis Enterprise Fund, Omega Funds, Pfizer Ventures, Piper Heartland, RA Capital Administration, Sofinnova Companions, Schroders Capital, and SV Well being Buyers.
“This Collection D accelerates our potential path to registration for each alnodesertib and ART6043, broadening improvement for the subsequent era of DNA harm response (DDR) therapeutics to indications among the many highest of unmet want throughout pancreatic, colorectal, and breast cancers, the place median survival is commonly measured in months,” stated Mike Andriole, Chief Government Officer of Artios.
In 2025, a number of European oncology-focused or adjoining BioTech startups secured notable funding rounds alongside Artios Pharma’s €99 million Collection D.
Germany’s Tubulis raised €308 million to advance its antibody-drug conjugate platform, whereas France’s Adcytherix secured €105 million to progress its novel ADC pipeline. The UK additionally noticed exercise by way of T-Therapeutics, which prolonged its Collection A to roughly €78.2 million for next-generation TCR-based therapies, and CHARM Therapeutics, which raised €68.5 million to develop remedies for resistant cancers. Switzerland’s NUCLIDIUM closed an €84 million Collection B for its radiopharmaceutical platform, and France’s Exeliom Biosciences raised €2.85 million to advance immuno-oncology improvement.
Collectively, these financings characterize roughly €646.6 million of capital flowing into European oncology and adjoining BioTech fields in 2025.
Artios’ €99 million increase represents a big addition to this sector and locations it within the higher echelon of funding rounds raised this yr.
Nikola Trbovic, Managing Associate, SV Well being Buyers, added, “We’re thrilled to have supported Artios’ evolution, from an early-stage DDR pioneer after we based the corporate to the established firm it has change into, distinguished by a promising and differentiated pipeline. We stay up for persevering with to take action because it deploys the Collection D proceeds to drive late-stage improvement of alnodesertib in addition to its pipeline.”
Based in 2016, Artios is innovating next-generation approaches within the (DDR) subject by way of its complete anti-cancer strategy and the deep expertise of its group of DDR drug builders.
The corporate’s clinical-stage candidates, ATR inhibitor alnodesertib and DNA Polymerase theta (Polθ) inhibitor ART6043, in addition to its pre-clinical packages, together with DDRi-ADCs, are designed with differentiated pharmaceutical properties and novel organic approaches to exactly eradicate a most cancers cell’s remaining survival mechanisms.
The Collection D proceeds will develop the scientific analysis of Artios’ lead program, alnodesertib, to enroll extra ATM-negative sufferers in every of second-line pancreatic most cancers and third-line colorectal most cancers, for which the programme was not too long ago granted U.S. FDA Quick Observe Designation.
On the AACR assembly in April 2025, Artios reported that alnodesertib, together with low-dose irinotecan, demonstrated a 50% confirmed total response charge in sufferers with ATM-negative stable tumors on the advisable Section 2 dose within the STELLA Section 1/2a trial.
There are at present no accepted therapies particularly for sufferers whose tumors harbor ATM-deficiency, a inhabitants the place alnodesertib has demonstrated sturdy responses throughout eight totally different stable tumors.
The proceeds from the financing may even be used to provoke a Section 2 randomised scientific trial for Artios’ second potential first-in-class candidate, ART6043, in sufferers with BRCA-mutant HER2-negative breast most cancers who’re eligible to obtain a PARP inhibitor. The DNA polymerase Theta (Polθ) inhibitor, ART6043, demonstrated a gorgeous tolerability profile, anticipated PK/PD exercise, and promising scientific alerts in information from a Section 1/2a examine offered on the ESMO Congress in September 2025.
The corporate can also be advancing a first-in-class and extremely differentiated DDR inhibitor-Antibody Drug Conjugate (DDRi-ADC) program and expects to call a lead candidate in Q1 2026.
Jake Simson, Associate, RA Capital Administration, commented, “We’re excited to co-lead this financing spherical to advance the subsequent era of DNA harm response therapeutics. Artios’ differentiated scientific programmes, alnodesertib and ART6043, collectively have the potential to meaningfully develop the influence of DDR-targeted therapies.
“The speed and sturdiness of responses noticed so far for alnodesertib throughout a variety of stable tumors and the early scientific outcomes with ART6043 underscore the energy of Artios’ strategy and skill to ship novel, probably first-in-class remedies for sufferers whereas constructing important long-term worth.”
